Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Alexander A. FitzpatrickChief Legal Officer | ARS PharmaceuticalsSPRY | Open-market sale10b5-1 plan | 06/12 | 06/12 | 3,355 sh | $10.00 | $33,550 | −3.6% |
Eric KarasChief Commercial Officer | ARS PharmaceuticalsSPRY | Open-market sale10b5-1 plan | 06/12 | 06/12 | 25,000 sh | $10.00 | $250,000 | −67.2% |
Brian DorseyCOO | ARS PharmaceuticalsSPRY | Open-market sale | 25/11/13 | 25/11/14 | 21,828 sh | $8.71 | $190,121.88 | −66.9% |
ARS PharmaceuticalsSPRY | Open-market sale | 25/11/12 | 25/11/14 | 166,380 sh2 trades | $8.87avg. | $1,475,626.8 | −100.0% | |
Richard E. LowenthalPresident and CEO | ARS PharmaceuticalsSPRY | Open-market sale10b5-1 plan | 25/08/21 | 25/08/22 | 50,000 sh | $14.49 | $724,500 | −4.0% |
ARS PharmaceuticalsSPRY | Open-market sale10b5-1 plan | 25/08/21 | 25/08/22 | 12,500 sh | $15.00 | $187,500 | −55.5% | |
ARS PharmaceuticalsSPRY | Open-market sale10b5-1 plan | 25/08/19–25/08/20 | 25/08/21 | 50,000 sh2 trades | $14.08avg. | $703,759.36 | −3.9% | |
Eric KarasChief Commercial Officer | ARS PharmaceuticalsSPRY | Open-market sale10b5-1 plan | 25/07/01 | 25/07/03 | 15,000 sh | $16.99 | $254,850 | −59.3% |
ARS PharmaceuticalsSPRY | Open-market sale | 25/06/27 | 25/07/01 | 740,149 sh2 trades | $18.46avg. | $13,663,150.54 | −13.2% | |
ARS PharmaceuticalsSPRY | Open-market sale | 25/06/27 | 25/07/01 | 740,149 sh2 trades | $18.46avg. | $13,663,150.54 | −13.2% | |
ARS PharmaceuticalsSPRY | Open-market sale | 25/06/27 | 25/07/01 | 740,149 sh2 trades | $18.46avg. | $13,663,150.54 | −13.2% | |
ARS PharmaceuticalsSPRY | Open-market sale | 25/06/27 | 25/07/01 | 740,149 sh2 trades | $18.46avg. | $13,663,150.54 | −13.2% | |
ARS PharmaceuticalsSPRY | Open-market sale | 25/06/27 | 25/07/01 | 740,149 sh2 trades | $18.46avg. | $13,663,150.54 | −13.2% | |
ARS PharmaceuticalsSPRY | Open-market sale | 25/06/27 | 25/07/01 | 740,149 sh2 trades | $18.46avg. | $13,663,150.54 | −13.2% | |
Eric KarasChief Commercial Officer | ARS PharmaceuticalsSPRY | Open-market sale10b5-1 plan | 25/06/18 | 25/06/20 | 15,000 sh | $16.00 | $240,000 | −66.1% |
Brent L. SaundersDirector | ARS PharmaceuticalsSPRY | Open-market sale | 25/05/20 | 25/05/22 | 120,000 sh | $14.25 | $1,710,000 | −100.0% |
Alexander A. FitzpatrickChief Legal Officer | ARS PharmaceuticalsSPRY | Open-market sale | 25/05/20 | 25/05/22 | 102,969 sh | $14.10 | $1,451,862.9 | −53.5% |
ARS PharmaceuticalsSPRY | Open-market sale | 25/05/20 | 25/05/22 | 50,000 sh | $14.10 | $705,000 | −87.1% | |
Shawver LauraDirector | ARS PharmaceuticalsSPRY | Open-market sale10b5-1 plan | 25/04/07 | 25/04/08 | 50,002 sh | $12.30 | $615,024.6 | −19.2% |
Eric KarasChief Commercial Officer | ARS PharmaceuticalsSPRY | Open-market sale10b5-1 plan | 25/03/20 | 25/03/21 | 10,000 sh | $14.00 | $140,000 | −56.5% |